Section 01 · Microbiology
H. pylori: The CagA Virulence Factor and Gastric Cancer Risk
Helicobacter pylori is a gram-negative, microaerophilic spiral bacterium that colonizes the gastric mucosa of an estimated 3.5 billion people globally. Prevalence is highest in South Asia, sub-Saharan Africa, and Latin America, where carriage rates exceed 70–80%, typically acquired in childhood through fecal-oral or oral-oral transmission in overcrowded conditions.
The organism's primary survival mechanism is a urease enzyme system that hydrolyzes urea into ammonia and carbon dioxide, creating a locally alkaline microenvironment that neutralizes gastric acid immediately around the bacterial colony. Flagella enable motility through the viscous mucus gel, and adhesins (particularly BabA and SabA) anchor the organism to blood group antigen receptors on the gastric epithelium.
The CagA Pathogenicity Island
Approximately 60–70% of Western H. pylori strains and over 90% of East Asian strains carry the cag pathogenicity island (PAI), a 40-kb genetic element encoding a type IV secretion system. This molecular syringe injects the CagA protein directly into host gastric epithelial cells, where it undergoes phosphorylation by Src and Abl kinases.
Phosphorylated CagA disrupts cell polarity via SHP-2 dephosphorylation of cytoskeletal proteins, promotes the hummingbird phenotype (elongated cell morphology), activates NF-κB-driven inflammation, and impairs epithelial tight junctions. Over decades, this sustained inflammation drives atrophic gastritis, intestinal metaplasia, and in a subset of patients, gastric adenocarcinoma — which kills over 700,000 people annually, making H. pylori a designated Group 1 carcinogen (IARC, 1994).
"CagA-positive strains increase gastric cancer risk 3–5-fold relative to CagA-negative strains. H. pylori eradication before atrophy develops reduces gastric cancer incidence by approximately 39% (Ford et al., Cochrane, 2020)."
Duodenal vs. Gastric Ulcer: The Same Bug, Different Mechanisms
H. pylori infection plays out differently depending on where it colonizes. In antral-predominant infection — more common in Western populations — the organism suppresses somatostatin-producing D cells, releasing the brake on gastrin secretion. Elevated gastrin drives hypersecretion of gastric acid, which overwhelms the duodenal bicarbonate buffer and causes duodenal ulcers (affecting 1–2% of infected individuals). In corpus-predominant or pangastric infection — more common in East Asia — acid output actually falls as oxyntic glands atrophy, but the risk of gastric ulcer and cancer rises markedly.
Stress ulcers are a distinct entity unrelated to H. pylori. Cushing's ulcers occur in neurosurgical and severe head-injury ICU patients: elevated intracranial pressure stimulates vagal hypersecretion of gastric acid via the dorsal nucleus. Curling's ulcers arise in major burn patients (>35% body surface area) through splanchnic vasoconstriction, mucosal ischemia, and reduced bicarbonate secretion. Both require prophylactic acid suppression in ICU settings.
Section 02 · Pharmacotherapy
Triple Therapy, Resistance Crisis & the Case for Bismuth Quadruple Regimens
Standard triple therapy — a proton pump inhibitor twice daily combined with clarithromycin 500mg and amoxicillin 1g, both twice daily, for 7–14 days — was the global default for H. pylori eradication for two decades. In the 1990s it achieved eradication rates of 90–95%. That era is over.
The Clarithromycin Resistance Crisis
Clarithromycin resistance in H. pylori arises through point mutations in the 23S rRNA gene (A2143G and A2142G being most common), which prevent clarithromycin from binding its ribosomal target. Resistance rates now exceed 15–20% across Europe and North America, and reach 30–40% in parts of Southern Europe and Southeast Asia. The European Registry on H. pylori Management (Hp-EuReg) reported that clarithromycin-based triple therapy achieved eradication in only 74.6% of cases in intention-to-treat analysis — below the 90% threshold considered acceptable for first-line treatment.
When clarithromycin resistance is present without testing, triple therapy eradication rates can fall below 50%, causing treatment failure, symptom persistence, selection of secondary resistance, and continued cancer risk.
Bismuth Quadruple Therapy
Bismuth quadruple therapy (BQT) combines a PPI with bismuth subsalicylate or subcitrate, tetracycline 500mg, and metronidazole 250–500mg, all four times daily for 10–14 days. It achieves eradication rates of 85–95% regardless of clarithromycin or metronidazole resistance status, because bismuth acts through multiple mechanisms independent of known resistance pathways: it disrupts bacterial cell walls, prevents urease activity, and inhibits H. pylori adherence.
The Maastricht VI/Florence consensus (European Helicobacter and Microbiota Study Group, 2022) now recommends BQT as preferred first-line therapy in regions where clarithromycin resistance exceeds 15%, or where susceptibility testing is unavailable. In the United States, the American College of Gastroenterology updated guidance in 2017 moved in the same direction.
Sequential and Concomitant Therapy
Sequential therapy delivers a PPI plus amoxicillin for 5 days, followed by a PPI plus clarithromycin plus metronidazole for 5 more days, on the premise that amoxicillin depletes efflux pumps that confer resistance to clarithromycin in the second phase. Initial meta-analyses showed superiority over triple therapy, but more recent data in high-resistance populations show eradication rates of 82–88%, not reliably superior to BQT. Concomitant (non-bismuth quadruple) therapy — PPI + clarithromycin + amoxicillin + metronidazole simultaneously — performs similarly.
Diagnosis: The Urea Breath Test and Stool Antigen Test
Accurate diagnosis matters because empirical treatment in test-negative patients is antibiotic overuse. The urea breath test (UBT) administers isotopically labeled urea (¹³C); if H. pylori is present, urease cleaves it and labeled CO₂ appears in exhaled breath within 20 minutes. Sensitivity 94–97%, specificity 95–97%. The stool antigen test (SAT) using monoclonal antibodies detects H. pylori antigens in feces with sensitivity and specificity above 94% and is preferred for post-eradication confirmation at least 4 weeks after completing antibiotics (and at least 2 weeks after stopping PPIs, which suppress urease activity and cause false negatives).
| Regimen | Duration | Expected Eradication | Resistance Risk | Guideline Status |
|---|---|---|---|---|
| Standard Triple Therapy PPI + clarithromycin + amoxicillin |
7–14 days | 74–80% | High (clarithromycin) | Avoid if local resistance >15% |
| Bismuth Quadruple Therapy PPI + bismuth + tetracycline + metro |
10–14 days | 85–95% | Low (resistance-independent) | Preferred first-line (Maastricht VI) |
| Sequential Therapy PPI+amox × 5d → PPI+clari+metro × 5d |
10 days | 82–88% | Moderate | Alternative in some guidelines |
| Concomitant (Non-Bismuth Quadruple) PPI + clari + amox + metro simultaneously |
10–14 days | 85–90% | Moderate | Alternative where bismuth unavailable |
| Levofloxacin Triple PPI + levofloxacin + amoxicillin |
10–14 days | 80–87% | Rising (quinolone resistance) | Rescue / second-line only |
Section 03 · Drug-Induced Ulcers
NSAID-Induced Ulcers: COX-1 Inhibition and Prostaglandin Depletion
Non-steroidal anti-inflammatory drugs are the second leading cause of peptic ulcer disease after H. pylori, responsible for approximately 25% of ulcers globally and a disproportionate share in older populations where NSAID use for arthritis is prevalent. Regular NSAID users face a 3–5-fold increased risk of serious peptic ulcer complications, including hemorrhage and perforation.
The COX-1 Mechanism
Cyclooxygenase exists in two isoforms. COX-2 is the inducible, pro-inflammatory isoform induced by cytokines at sites of tissue injury — the target responsible for NSAID analgesia and anti-inflammatory effects. COX-1 is the constitutive isoform expressed continuously in gastric epithelium and platelets. NSAIDs inhibit both isoforms, but it is COX-1 inhibition that drives gastrointestinal toxicity.
COX-1-derived prostaglandins (principally PGE₂ and PGI₂) serve three critical cytoprotective functions in the gastric mucosa: they stimulate mucus and bicarbonate secretion from surface epithelial cells, maintain mucosal microvascular blood flow, and promote epithelial proliferation and repair. When NSAIDs suppress COX-1, these defenses collapse: the mucus layer thins, bicarbonate secretion falls, submucosal blood flow decreases, and acid — whose secretion is unaffected — meets an unprotected epithelium.
Topical mucosal damage from direct NSAID contact (NSAIDs are weak acids that enter cells in the acidic gastric environment and ionize, trapping them intracellularly) compounds the systemic COX-1 inhibition effect, which is why enteric-coated formulations reduce gastric erosions but do not eliminate ulcer risk.
Selective COX-2 Inhibitors and Cardiovascular Risk
Celecoxib and other selective COX-2 inhibitors (coxibs) spare COX-1, substantially reducing gastrointestinal mucosal toxicity compared to non-selective NSAIDs. The CLASS trial (JAMA, 2000) and VIGOR trial (NEJM, 2000) confirmed this. However, selective COX-2 inhibition also suppresses prostacyclin (PGI₂) in endothelium without reducing thromboxane A₂ in platelets (a COX-1 product), shifting the hemostatic balance toward prothrombotic states — explaining the increased cardiovascular risk that led to rofecoxib withdrawal in 2004. For patients requiring long-term NSAIDs, co-prescription of a PPI substantially reduces ulcer risk but does not restore mucosal prostaglandins.
Section 04 · Acid Suppression
Proton Pump Inhibitors: Mechanism, Therapeutic Role & Long-Term Risks
Proton pump inhibitors are the most prescribed class of drugs in the developed world. They work by irreversibly binding the H⁺/K⁺-ATPase (the proton pump) on the luminal surface of gastric parietal cells, preventing hydrogen ion secretion into the gastric lumen. Because the drug must be absorbed and activate in the acidic secretory canaliculi of parietal cells, PPIs are prodrugs that require conversion to their active sulfonamide form at pH below 2.
PPIs are essential in peptic ulcer treatment: as part of H. pylori eradication regimens (acid suppression raises intragastric pH above 4, improving antibiotic stability and bioavailability); as monotherapy for NSAID-induced and non-H. pylori, non-NSAID ulcers; and in maintenance to prevent ulcer recurrence in high-risk patients. They reduce gastric acid output by 80–95% at standard doses.
Long-Term Risks: The Evidence Landscape
The risks of long-term PPI use (generally defined as beyond 8–12 weeks at therapeutic doses) are now well-characterized in epidemiological literature, though causality is debated because PPI users tend to be older with more comorbidities.
Vitamin B12 deficiency: Gastric acid is required to cleave cobalamin from dietary protein via pepsin. PPIs impair this step, reducing B12 absorption from food (crystalline B12 supplements are unaffected). A 2013 JAMA study (Lam et al.) found a 65% increased odds of B12 deficiency with PPI use for more than 2 years, particularly at higher doses.
Hypomagnesemia: PPIs reduce intestinal magnesium absorption through mechanisms not fully understood. The FDA issued a safety alert in 2011 after reports of severe hypomagnesemia causing arrhythmias, muscle spasm, and seizures, particularly in patients on long-term therapy or concurrent digoxin/diuretics. Monitoring serum magnesium is recommended for long-term users.
Bone fracture risk: Hypochlorhydria reduces calcium dissolution and absorption, and acid suppression may inhibit osteoclast proton pumps. Multiple observational studies report 10–40% increased hip fracture risk with long-term PPI use, particularly at high doses. The clinical significance in average-risk patients is modest but warrants consideration in elderly women on chronic therapy.
Gut microbiome disruption: The gut microbiome is substantially shaped by pH throughout the GI tract. PPI-induced hypochlorhydria permits oral and upper GI bacteria to reach the lower intestine, reducing microbiome diversity and increasing susceptibility to small intestinal bacterial overgrowth (SIBO) and Clostridioides difficile infection. A large 2016 gut microbiome study (Jackson et al.) found PPI use was the strongest drug-associated predictor of microbiome composition changes, independent of antibiotic use.
"PPIs are appropriate and effective for the durations studied in RCTs — typically 4–8 weeks. Indefinite continuation without ongoing indication is where risk accumulates. Step-down and deprescribing should be revisited at every patient encounter."
Section 05 · Dietary & Natural Interventions
Sulforaphane, Manuka Honey & Mastic Gum: What the Evidence Actually Shows
The gap between popular claims and clinical evidence is wide in gut health nutrition. Three dietary agents have accumulated enough mechanistic and human data to warrant serious consideration as adjuncts — not replacements — for standard H. pylori treatment.
Broccoli Sprout Sulforaphane
Sulforaphane, an isothiocyanate derived by myrosinase-catalyzed hydrolysis of glucoraphanin in cruciferous vegetables, demonstrates potent bactericidal activity against H. pylori in vitro, including against clarithromycin-resistant strains, with minimum inhibitory concentrations (MICs) in the range of 1–4 μg/mL. Its mechanism is distinct from antibiotics: sulforaphane inhibits bacterial urease directly and disrupts H. pylori biofilms.
The landmark human trial (Yanaka et al., Cancer Prevention Research, 2009) enrolled 50 H. pylori-positive patients in Japan in a randomized double-blind study. Participants consumed either 70g of broccoli sprouts (containing ~420μmol glucoraphanin) or alfalfa sprouts daily for 8 weeks. The broccoli sprout group showed a statistically significant reduction in urease breath test values and in H. pylori stool antigen levels, along with reduced serum pepsinogen I/II ratio (a marker of gastric inflammation). Critically, 8 of 25 patients in the broccoli group converted to H. pylori negative, compared to 1 of 25 in the control group. All reverted to positive after the intervention ended, suggesting suppression rather than eradication — but clinically relevant suppression of colonization density and associated inflammation.
Broccoli sprouts contain 20–50 times more glucoraphanin than mature broccoli. Mature broccoli florets have substantially lower bioactive sulforaphane potential, particularly when cooked (myrosinase is heat-sensitive). Supplemental sulforaphane or stabilized glucoraphanin with added myrosinase (e.g., myrosinase-containing mustard seed powder) can reliably deliver consistent doses.
Manuka Honey
Manuka honey (from Leptospermum scoparium) contains methylglyoxal (MGO) as its primary bioactive compound, distinct from the hydrogen peroxide-based activity of conventional honey. In vitro studies demonstrate inhibitory activity against H. pylori at concentrations as low as 5% w/v, with MIC values of approximately 5–10% (Osato et al., 1999; Ndip et al., 2007). No large randomized clinical trials in humans have confirmed eradication benefit, and achieving therapeutic concentrations in gastric mucosa through dietary intake is pharmacokinetically implausible. Manuka honey should be viewed as supportive for mucosal healing — it has independently documented wound-healing, anti-inflammatory, and prebiotic properties — not as an antibiotic equivalent.
Mastic Gum
Mastic is a resin from Pistacia lentiscus trees native to the Greek island of Chios. A 1998 New England Journal of Medicine letter (Huwez et al.) reported that mastic killed H. pylori in vitro at concentrations as low as 125 μg/mL — a striking result. Subsequent in vivo work has been more ambiguous. A randomized controlled trial (Bebb et al., 2003) found no significant H. pylori eradication with mastic gum monotherapy at 350mg three times daily for 14 days vs. placebo. However, combinations of mastic with standard regimens or higher doses may offer mucosal cytoprotection and anti-inflammatory benefit (shown in a 2016 systematic review by Dabos et al.) even without direct bactericidal activity in the concentrations achievable in vivo. Mastic gum appears useful as an adjunct, particularly for mucosal healing and symptom relief.
| Intervention | Mechanism | Best Evidence | Clinical Evidence Level | Practical Use |
|---|---|---|---|---|
| Broccoli sprout sulforaphane | Urease inhibition, biofilm disruption | Yanaka et al., 2009 (RCT, n=50) | Moderate — suppression, not eradication | 70g sprouts/day or supplement |
| Manuka honey (MGO) | Methylglyoxal bactericidal activity | In vitro MIC data (Osato 1999, Ndip 2007) | Low — no RCT eradication data | Adjunct for mucosal healing |
| Mastic gum | Membrane disruption (in vitro) | Bebb et al., 2003 (RCT — negative) | Mixed — adjunct benefit possible | Adjunct, not monotherapy |
| Lactobacillus reuteri / rhamnosus | Competitive exclusion, mucus support | Multiple RCTs (Dajani 2013, Zheng 2019) | Moderate — eradication rate +5–8% as adjunct | Co-administer with antibiotics |
The GutCode H. pylori Protocol
- Test first. Confirm H. pylori with urea breath test or monoclonal stool antigen test before starting antibiotics. Avoid testing within 2 weeks of PPI use or 4 weeks of antibiotic use.
- Choose therapy by local resistance data. If clarithromycin resistance exceeds 15% in your region (much of North America, Europe), bismuth quadruple therapy for 14 days is preferred over standard triple therapy.
- Verify eradication. Retest with UBT or SAT at least 4 weeks post-antibiotics and 2 weeks after stopping PPIs. Treatment failure is common and requires salvage therapy.
- Audit NSAID use. If ulcers persist or recur and H. pylori is negative, evaluate NSAID exposure including OTC ibuprofen and aspirin. Co-prescribe a PPI if NSAIDs are essential.
- Limit long-term PPI use. Use PPIs for the minimum effective duration. Step down to H₂ blockers or on-demand dosing when maintenance is required. Monitor B12 and magnesium annually in long-term users.
- Dietary adjuncts as support, not substitutes. Broccoli sprouts (70g/day or equivalent supplement), Lactobacillus reuteri (2×10⁸ CFU/day with meals), and mastic gum (500mg twice daily) are reasonable adjuncts during and after eradication therapy to reduce colonization density and support mucosal healing.
- Screen high-risk patients. If you are in East Asia or have a family history of gastric cancer, discuss H. pylori screening and eradication with your gastroenterologist regardless of symptoms — precancerous atrophy is reversible if caught before intestinal metaplasia.